These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3315610)

  • 1. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
    Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
    Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
    Anderson JL
    Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML; Quilliet L; Kulbertus H; Materne P; Letac B; Cribier A; Monassier JP; Sacrez A; Favier JP
    Drugs; 1987; 33 Suppl 3():140-5. PubMed ID: 3315581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Timmis AD; Griffin B; Crick JC; Flax JS; Sowton E
    Drugs; 1987; 33 Suppl 3():146-50. PubMed ID: 3315582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
    Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Rothbard RL
    Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
    Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ
    Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
    Bonnier JJ
    Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early clinical evaluation of the intravenous treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Chen C; Hofmann T; Zeiher A; Drexler H; Just H
    Drugs; 1987; 33 Suppl 3():112-6. PubMed ID: 3315575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
    Meinertz T; Kasper W; Schumacher M; Just H
    Am J Cardiol; 1988 Sep; 62(7):347-51. PubMed ID: 3046283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Kaspar L; Karnik R; Sehnal E; Zajicek P; Ziegler B; Slany J
    Drugs; 1987; 33 Suppl 3():179-82. PubMed ID: 3315588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Jackson D
    Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.